Findings

What do systematic reviews say?

182 questions · 189 findings · 24 reviews · Pain, Palliative and Supportive Care

Sort:Best matchNewest Highest certainty Download CSV

No studies found 20 · 10.6%GRADE not reported 3 · 1.6%Very low 54 · 28.6%Low 62 · 32.8%Moderate 43 · 22.8%High 7 · 3.7%

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

aprepitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

aprepitant + ramosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

fosaprepitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

netupitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
High

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

fosaprepitant + granisetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
High

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

aprepitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

fosaprepitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Low

Intervention not reported

Total studies: 42 Total participants: 14,626 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…

The intervention led to lower total studies: 42 Total participants: 14,626; GRADE not reported.

1 finding from 1 review

Antidepressants for pain management in adults with chronic pain: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
42 participants
GRADE not reported

Intervention not reported

Total studies: 50 Total participants: 14,926 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…

1 finding from 1 review

Antidepressants for pain management in adults with chronic pain: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
50 participants
GRADE not reported

Intervention not reported

Duloxetine standard dose RCTs: 18 Participants: 4959 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…

1 finding from 1 review

Antidepressants for pain management in adults with chronic pain: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
18 participants
Moderate

Intervention not reported

Milnacipran standard dose RCTs: 4 Participants: 1866 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…

1 finding from 1 review

Antidepressants for pain management in adults with chronic pain: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
4 participants
Moderate

Intervention not reported

Duloxetine low dose RCTs: 6 Participants: 1104 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…

1 finding from 1 review

Antidepressants for pain management in adults with chronic pain: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
6 participants
Moderate

Intervention not reported

Duloxetine standard dose RCTs: 16 Participants: 4490 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…

1 finding from 1 review

Antidepressants for pain management in adults with chronic pain: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
16 participants
Moderate

Intervention not reported

Total studies: 93 Total participants: 22,558 · people with chronic pain Interventions: amitriptyline standard dose (25‐75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (<…

The intervention led to lower total studies: 93 Total participants: 22,558; GRADE not reported.

1 finding from 1 review

Antidepressants for pain management in adults with chronic pain: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
93 participants
GRADE not reported

Intervention not reported

Mirtazapine standard dose RCTs: 2 Participants: 457 · people with chronic pain Interventions: amitriptyline standard dose (25‐75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (<…

1 finding from 1 review

Antidepressants for pain management in adults with chronic pain: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 participants
Very low

Intervention not reported

Duloxetine standard dose RCTs: 20 Participants: 4998 · people with chronic pain Interventions: amitriptyline standard dose (25‐75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (<…

1 finding from 1 review

Antidepressants for pain management in adults with chronic pain: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
20 participants
Very low

Intervention not reported

Milnacipran standard dose RCTs: 8 Participants: 2491 · people with chronic pain Interventions: amitriptyline standard dose (25‐75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (<…

1 finding from 1 review

Antidepressants for pain management in adults with chronic pain: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
8 participants
Very low

Intervention not reported

Duloxetine low dose RCTs: 6 Participants: 1031 · people with chronic pain Interventions: amitriptyline standard dose (25‐75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (<…

1 finding from 1 review

Antidepressants for pain management in adults with chronic pain: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
6 participants
Very low

Intervention not reported

Amitriptyline standard dose RCTs: 10 Participants: 997 · people with chronic pain Interventions: amitriptyline standard dose (25‐75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (<…

1 finding from 1 review

Antidepressants for pain management in adults with chronic pain: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
10 participants
Very low

Intervention not reported

Esreboxetine standard dose RCTs: 1 Participants: 783 · people with chronic pain Interventions: amitriptyline standard dose (25‐75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (<…

1 finding from 1 review

Antidepressants for pain management in adults with chronic pain: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 participants
Very low